The altered expression of iron metabolism-related proteins in almost all of the canine testicular neoplasia suggests their significance as potential therapeutic targets; therefore, the delivery of transferrin-chemotherapic conjugates via TfR1 should be considered in canine testicular cancers. Here, TFRC is linked to testicular cancer.